Loading...
As more women survive malignancies diagnosed during their reproductive years, fertility preservation has received growing emphasis — especially for women who receive chemotherapy with alkylating agents such as cyclophosphamide, which damage and destroy oocytes. Egyptian investigators conducted a randomized trial to determine if ovarian suppression with a gonadotropin-releasing hormone (GnRH) agonist could prevent ovarian damage (manifested as amenorrhea) associated with chemotherapy for primary hormone-insensitive breast cancer.
Of 100 women (mean age, 32) scheduled for 6 cycles of 5-fluorouracil, adriamycin, and cyclophosphamide, 50 received chemotherapy within 1 week of study enrollment (randomized 1:1 to chemotherapy alone or following co…